Tag: ductalBreastCancer

Articles

• Breast cancer types
• Ductal breast cancer and DCIS characteristics
• Tumor characteristics influencing prognosis of triple negative BC
• Tumor proliferation, as measured by Ki-67, predicts BC outcomes

News

03/16/14

Over 80% of women diagnosed with DCIS or LCIS do not progress

01/12/14

Almost 1-in-3 relapse if no radiation after lumpectomy for DCIS

10/30/12

Prognosis of triple negative BC varies according histological type

06/25/12

Lobular breast cancer has less favorable prognosis than expected

12/04/11

Lumpectomy vs. mastectomy rates vary by type of breast cancer

11/05/11

Luminal BC prognosis can vary based on other tumor characteristics

01/26/11

Intense hot flashes at menopause linked to lower breast cancer risk

10/18/10

Women with DCIS and dense breasts have a higher risk of additional BC

Studies

• Treatment and survival differences between patients with invasive lobular carcinoma versus invasive ductal carcinoma of the breast Cite
  Anampa JD, Lin S, Obeng-Gyasi S, Xue X. Treatment and survival differences between patients with invasive lobular carcinoma versus invasive ductal carcinoma of the breast. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2024; 10.1158/1055-9965.epi-24-1250
• Comparative Analysis of Vitamin D, Folic Acid, and Trace Minerals Levels in Various Stages of Invasive Ductal Breast Cancer Cite
  Helena V, Arumugam S, Muninathan N, Baskaran K, Tasneem A. Comparative Analysis of Vitamin D, Folic Acid, and Trace Minerals Levels in Various Stages of Invasive Ductal Breast Cancer. Cureus. Springer Science and Business Media LLC; 2024; 10.7759/cureus.70593
• Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials Cite
  Foldi J, Carleton N, Anderson SJ, Rastogi P, Lee A, Balic M, et al. Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae188
• Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations Cite
  Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, et al. Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2024; 121 10.1073/pnas.2322068121
• Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance Cite
  Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S, et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduction and Targeted Therapy. Springer Science and Business Media LLC; 2024; 9 10.1038/s41392-024-01779-3
• Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis Cite
  Alkhafaji S, Wolf DM, Magbanua MJM, J. van ‘t Veer L, Park JW, Esserman L, et al. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. npj Breast Cancer. Springer Science and Business Media LLC; 2024; 10 10.1038/s41523-024-00623-9
• Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer Cite
  CAVALLER L, GOUPILLE C, ARBION F, VILDE A, BODY G, OULDAMER L. Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2024;:102740 10.1016/j.jogoh.2024.102740
• Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer Cite
  Göker M, Denys H, Hendrix A, De Wever O, Van de Vijver K, Braems G. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01745-x
• Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma Cite
  Yoon TI, Jeong J, Lee S, Ryu JM, Lee YJ, Lee JY, et al. Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma. JAMA Network Open. American Medical Association (AMA); 2023; 6:e2342270 10.1001/jamanetworkopen.2023.42270
• Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I–III MIDLC Patients Cite
  Lohani KR, Hoskin TL, Day CN, Yasir S, Boughey JC, Degnim AC. Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I–III MIDLC Patients. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14455-7
• Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases Cite
  Chen B, Tsai Y, Lien P, Lin Y, Feng C, Chen Y, et al. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 201:547-560 10.1007/s10549-023-07044-5
• Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry Cite
  Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07022-x
• Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) Cite
  Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01626-3
• Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma Cite
  Nasrazadani A, Li Y, Fang Y, Shah O, Atkinson JM, Lee JS, et al. Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-022-02131-8
• Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence Cite
  O’Keefe TJ, Chau H, Harismendy O, Wallace AM. Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence. Surgery. Elsevier BV; 2022; 10.1016/j.surg.2022.10.009
• Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer Cite
  Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, et al. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2022; 10.1093/jnci/djac157
• Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS Cite
  Nakhlis F, Katlin FD, Grossmith SC, DiPasquale A, Harrison BT, Schnitt SJ, et al. Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-12066-2
• Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma Cite
  Nakayama S, Masuda H, Miura S, Kuwayama T, Hashimoto R, Taruno K, et al. Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma. Breast Cancer. Springer Science and Business Media LLC; 2022; 29:610-617 10.1007/s12282-022-01338-0
• Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer Cite
  Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics. Springer Science and Business Media LLC; 2022; 54:850-860 10.1038/s41588-022-01082-3
• Adherence to a western dietary pattern and risk of invasive ductal and lobular breast carcinomas: a case–control study Cite
  Foroozani E, Akbari A, Amanat S, Rashidi N, Bastam D, Ataee S, et al. Adherence to a western dietary pattern and risk of invasive ductal and lobular breast carcinomas: a case–control study. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-09725-5
• Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status Cite
  Hills RK, Oesterreich S, Metzger O, Dabbs D, Pan H, Braybrooke J, et al. Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:PD14-08-PD14-08 10.1158/1538-7445.sabcs21-pd14-08
• Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population Cite
  Kwon D, Ko BK, Jung SP, Kim H, Kim E, Jung YS, et al. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0262709 10.1371/journal.pone.0262709
• Clinical Differences between Invasive Lobular Breast Cancer and Invasive Carcinoma of No Special Type in the German Mammography-Screening-Program Cite
  Farrokh A, Goldmann G, Meyer-Johann U, Hille-Betz U, Hillemanns P, Bader W, et al. Clinical Differences between Invasive Lobular Breast Cancer and Invasive Carcinoma of No Special Type in the German Mammography-Screening-Program. Women & Health. Informa UK Limited; 2022;:1-13 10.1080/03630242.2022.2030448
• Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis Cite
  O'Connor DJ, Davey MG, Barkley LR, Kerin MJ. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis. The Breast. Elsevier BV; 2022; 61:1-10 10.1016/j.breast.2021.11.017
• The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution Cite
  WATANABE J, NAKAMOTO S, SUGINO T. The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution. Anticancer Research. Anticancer Research USA Inc.; 2021; 41:4619-4627 10.21873/anticanres.15275
• Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up Cite
  Chamalidou C, Fohlin H, Albertsson P, Arnesson L, Einbeigi Z, Holmberg E, et al. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. The Breast. Elsevier BV; 2021; 10.1016/j.breast.2021.07.011
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Hautakoski A, Marttila M, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-88488-x
• Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients Cite
  Stanton SE, Gad E, Ramos E, Corulli L, Annis J, Childs J, et al. Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00257-1
• Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma Cite
  Hills N, Leslie M, Davis R, Crowell M, Kameyama H, Rui H, et al. Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-09747-9
• Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer Cite
  Giardiello D, Kramer I, Hooning MJ, Hauptmann M, Lips EH, Sawyer E, et al. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-00202-8
• Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma Cite
  Lee J, Jung JH, Kim WW, Park CS, Lee RK, Kim HJ, et al. Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07443-7
• Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis Cite
  Dianatinasab M, Rezaian M, HaghighatNezad E, Bagheri-Hosseinabadi Z, Amanat S, Rezaeian S, et al. Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis. Clinical Breast Cancer. Elsevier BV; 2020; 20:e516-e528 10.1016/j.clbc.2020.03.007
• The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast Cite
  Zhao H. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast. Breast Cancer. Springer Science and Business Media LLC; 2020; 10.1007/s12282-020-01146-4
• A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer Cite
  Wang Z, Wang H, Ding X, Chen X, Shen K. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592093267 10.1177/1758835920932674
• Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact Cite
  Schnitt SJ, Moran MS, Giuliano AE. Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:2240-2245 10.1200/jco.19.03213
• Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study Cite
  Sundelin EIO, al-Suliman N, Vahl P, Vendelbo M, Munk OL, Jakobsen S, et al. Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:107-113 10.1007/s10549-020-05621-6
• Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers Cite
  Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, et al. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:735-745 10.1007/s10549-020-05565-x
• Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort Cite
  Puvanesarajah S, Gapstur SM, Gansler T, Sherman ME, Patel AV, Gaudet MM. Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2019; 31:95-103 10.1007/s10552-019-01253-4
• The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women Cite
  Katuwal S, Tapanainen JS, Pukkala E, Kauppila A. The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-5404-z
• Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study Cite
  Wang K, Zhu G, Shi Y, Li Z, Zhang X, Li H. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study. Clinical Breast Cancer. Elsevier BV; 2019; 19:e101-e115 10.1016/j.clbc.2018.10.010
• Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens Cite
  Rageth CJ, Rubenov R, Bronz C, Dietrich D, Tausch C, Rodewald A, et al. Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens. Breast Cancer. Springer Science and Business Media LLC; 2018; 26:452-458 10.1007/s12282-018-00943-2
• Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast Cite
  Morrow E, Lannigan A, Doughty J, Litherland J, Mansell J, Stallard S, et al. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. British Journal of Surgery. Wiley; 2018; 105:987-995 10.1002/bjs.10791
• Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14–25) Cite
  Cho WK, Choi DH, Lee J, Park W, Kim YB, Suh C, et al. Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14–25). The Breast. Elsevier BV; 2018; 38:165-170 10.1016/j.breast.2018.01.004
• Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 Cite
  Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd L, O'Shaughnessy J, Parulekar W, et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. European Journal of Cancer. Elsevier BV; 2018; 90:19-25 10.1016/j.ejca.2017.11.014
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study Cite
  Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, et al. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2017; 29:25-32 10.1007/s10552-017-0977-9
• Association between unilateral or bilateral mastectomy and breast cancer death in patients with unilateral ductal carcinoma Cite
  Agarwal S, Pappas L, Agarwal J. Association between unilateral or bilateral mastectomy and breast cancer death in patients with unilateral ductal carcinoma. Cancer Management and Research. Informa UK Limited; 2017; Volume 9:649-656 10.2147/cmar.s148456
• Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma Cite
  Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, et al. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0182397 10.1371/journal.pone.0182397
• Breast Cancer Survival is Improved When DCIS Accompanies Invasive Ductal Carcinoma Cite
  Kole A, Park H, Johnson S, Kelly J, Patel A. Breast Cancer Survival is Improved When DCIS Accompanies Invasive Ductal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 99:E25 10.1016/j.ijrobp.2017.06.651
• Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status Cite
  Xiao Y, Ma D, Ruan M, Zhao S, Liu X, Jiang Y, et al. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/s41598-017-10789-x
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years Cite
  Baglia ML, Malone KE, Tang MC, Li CI. Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years. Hormones and Cancer. Springer Science and Business Media LLC; 2017; 8:211-218 10.1007/s12672-017-0297-2
• Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast Cite
  Marmor S, Hui JYC, Huang JL, Kizy S, Beckwith H, Blaes AH, et al. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer. Wiley; 2017; 123:3015-3021 10.1002/cncr.30699
• Abstract P1-07-08: Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology Cite
  McCart Reed A, Kutasovic J, Nones K, da Silva L, Melville L, Jayanthan J, et al. Abstract P1-07-08: Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p1-07-08
• Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers Cite
  Lobbes MB, Vriens IJ, van Bommel AC, Nieuwenhuijzen GA, Smidt ML, Boersma LJ, et al. Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 162:353-364 10.1007/s10549-017-4117-8
• Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Cite
  Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, et al. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:587-596 10.1007/s10549-016-3845-5
• Co-prevalence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer Cite
  Al Moustafa A, Al-Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A. Co-prevalence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. Human Vaccines & Immunotherapeutics. Informa UK Limited; 2016;:1-4 10.1080/21645515.2016.1139255
• Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population Cite
  Lim ST, Choi JE, Kim SJ, Kim HA, Kim JY, Park HK, et al. Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:473-483 10.1007/s10549-016-3771-6
• Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer Cite
  Truin W, Roumen RM, Siesling S, van der Heiden-van der Loo M, Lobbezoo DJ, Tjan-Heijnen VC, et al. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:e75-e82 10.1016/j.clbc.2016.03.007
• Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma Cite
  Adachi Y, Ishiguro J, Kotani H, Hisada T, Ichikawa M, Gondo N, et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2275-4
• Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction Cite
  Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, et al. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0145534 10.1371/journal.pone.0145534
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Cite
  Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2772-2779 10.1200/jco.2015.60.8133
• Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncologica. Informa UK Limited; 2015; 55:188-192 10.3109/0284186x.2015.1062538
• The organochlorine pesticides residues in the invasive ductal breast cancer patients Cite
  Yang J, Wang Z, Ma L, Shen X, Sun Y, Hu D, et al. The organochlorine pesticides residues in the invasive ductal breast cancer patients. Environmental Toxicology and Pharmacology. Elsevier BV; 2015; 40:698-703 10.1016/j.etap.2015.07.007
• Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry Cite
  Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:143 10.4048/jbc.2015.18.2.143
• Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Case–Control Study Cite
  Chen L, Malone KE, Li CI. Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2014; 23:2181-2185 10.1158/1055-9965.epi-14-0414
• Alcohol and Risk of Breast Cancer in Postmenopausal Women: An Analysis of Etiological Heterogeneity by Multiple Tumor Characteristics Cite
  Falk RT, Maas P, Schairer C, Chatterjee N, Mabie JE, Cunningham C, et al. Alcohol and Risk of Breast Cancer in Postmenopausal Women: An Analysis of Etiological Heterogeneity by Multiple Tumor Characteristics. American Journal of Epidemiology. Oxford University Press (OUP); 2014; 180:705-717 10.1093/aje/kwu189
• The sensitivity of pre-operative axillary staging in breast cancer: Comparison of invasive lobular and ductal carcinoma Cite
  Topps A, Clay V, Absar M, Howe M, Lim Y, Johnson R, et al. The sensitivity of pre-operative axillary staging in breast cancer: Comparison of invasive lobular and ductal carcinoma. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:813-817 10.1016/j.ejso.2014.03.026
• Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival Cite
  Dieterich M, Hartwig F, Stubert J, Klöcking S, Kundt G, Stengel B, et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. The Breast. Elsevier BV; 2014; 23:346-351 10.1016/j.breast.2014.01.015
• Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years Cite
  Li CI, Daling JR, Tang MC, Haugen KL, Porter PL, Malone KE. Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years. JAMA Internal Medicine. American Medical Association (AMA); 2013; 173:1629 10.1001/jamainternmed.2013.9071
• The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients Cite
  Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo E, Holli K, Kallioniemi A, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. The Breast. Elsevier BV; 2013; 22:1119-1124 10.1016/j.breast.2013.06.001
• Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age Cite
  McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI. Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:1529-1537 10.1158/1055-9965.epi-13-0414
• Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies Cite
  Collaborative Group on Hormonal Factors in Breast Cancer . Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology. Elsevier BV; 2012; 13:1141-1151 10.1016/s1470-2045(12)70425-4
• Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome Cite
  Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, et al. Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. Clinical Breast Cancer. Elsevier BV; 2013; 13:31-39 10.1016/j.clbc.2012.09.002
• Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions Cite
  Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3222
• Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer Cite
  Truin W, Voogd A, Vreugdenhil G, van der Heiden-van der Loo M, Siesling S, Roumen R. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:2859-2865 10.1093/annonc/mds180
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102
• Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer Cite
  Mangé A, Lacombe J, Bascoul-Mollevi C, Jarlier M, Lamy P, Rouanet P, et al. Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2012; 18:1992-2000 10.1158/1078-0432.ccr-11-2527
• S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. Cite
  Solin L, Gray R, Baehner F, Butler S, Badve S, Yoshizawa C, et al. S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194.. General Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-s4-6
• Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique? Cite
  Wasif N, McCullough AE, Gray RJ, Pockaj BA. Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique?. Journal of Surgical Oncology. Wiley; 2011; 105:586-590 10.1002/jso.22132
• Outcome of special types of luminal breast cancer Cite
  Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua M, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:1428-1436 10.1093/annonc/mdr461
• Should palpable DCIS be treated as IDC? A retrospective audit. Cite
  Nair NS, Pandey N, Vanmali V, Shet T, Hawaldar R, Parmar V, et al. Should palpable DCIS be treated as IDC? A retrospective audit.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:146-146 10.1200/jco.2011.29.27_suppl.146
• Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers. Cite
  Ambros T, Sujoy V, Fernandez CG, Reis I, Wright JL, Jorda M, et al. Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:132-132 10.1200/jco.2011.29.27_suppl.132
• Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer Cite
  Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, et al. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2011; 29:1536-1542 10.1007/s12032-011-0082-y
• Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period Cite
  Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, et al. Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:1107-1114 10.1245/s10434-011-1907-9
• Axillary node staging for microinvasive breast cancer: Is it justified? Cite
  Lyons JM, Stempel M, Van Zee KJ, Cody HS. Axillary node staging for microinvasive breast cancer: Is it justified?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:7-7 10.1200/jco.2011.29.27_suppl.7
• Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients Cite
  Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, et al. Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:519-526 10.1245/s10434-011-1879-9
• Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast Cite
  Fernandez B, Paish EC, Green AR, Lee AHS, Macmillan RD, Ellis IO, et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. Journal of Clinical Pathology. BMJ; 2011; 64:995-1000 10.1136/jclinpath-2011-200151
• Radiation and survival in women over 70 with T1 N0 M0 ER-negative breast cancer from 1990 to 2007: A population-based analysis. Cite
  Wojcieszynski AP, Shen X, Mishra MV, Anne PR, Showalter TN. Radiation and survival in women over 70 with T1 N0 M0 ER-negative breast cancer from 1990 to 2007: A population-based analysis.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1037-1037 10.1200/jco.2011.29.15_suppl.1037
• Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas Cite
  Catasus L, Gallardo A, Llorente-Cortes V, Escuin D, Muñoz J, Tibau A, et al. Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas. Human Pathology. Elsevier BV; 2011; 42:1581-1588 10.1016/j.humpath.2011.01.011
• Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review Cite
  Hussain M, Cunnick G. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:279-289 10.1016/j.ejso.2011.01.009
• Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer Cite
  Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI. Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:379-388 10.1158/1055-9965.epi-10-0998
• Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Cite
  Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. The Lancet Oncology. Elsevier BV; 2011; 12:21-29 10.1016/s1470-2045(10)70266-7
• Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ Cite
  Habel LA, Capra AM, Achacoso NS, Janga A, Acton L, Puligandla B, et al. Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2488-2495 10.1158/1055-9965.epi-10-0769
• Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study Cite
  Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, et al. Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:1422-1431 10.1093/jnci/djq316
• Alcohol Consumption and Risk of Ductal Carcinoma In situ of the Breast in a Cohort of Postmenopausal Women Cite
  Kabat GC, Kim M, Shikany JM, Rodgers AK, Wactawski-Wende J, Lane D, et al. Alcohol Consumption and Risk of Ductal Carcinoma In situ of the Breast in a Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2066-2072 10.1158/1055-9965.epi-10-0388
• Micronutrient intake and breast cancer characteristics among postmenopausal women Cite
  Roswall N, Olsen A, Christensen J, Dragsted LO, Overvad K, Tjønneland A. Micronutrient intake and breast cancer characteristics among postmenopausal women. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2010; 19:360-365 10.1097/cej.0b013e32833ade68
• The impact of young age on breast cancer outcome Cite
  Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, et al. The impact of young age on breast cancer outcome. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2010; 36:639-645 10.1016/j.ejso.2010.05.016
• Specialty Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort Cite
  Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Specialty Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1696-1708 10.1158/1055-9965.epi-10-0318
• Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population Cite
  Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DSM. Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1643-1654 10.1158/1055-9965.epi-10-0188
• Characteristics and outcomes of invasive lobular of carcinoma and invasive ductal carcinoma of the breast: SEER/Medicare 1992-2002. Cite
  Thomas A, Xie Y, Wright KB, Brooks J. Characteristics and outcomes of invasive lobular of carcinoma and invasive ductal carcinoma of the breast: SEER/Medicare 1992-2002.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e16520-e16520 10.1200/jco.2010.28.15_suppl.e16520
• Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter? Cite
  Muhsen S, Morrogh M, Andrade AP, Sakr R, Paik W, Morrow M, et al. Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1593-1593 10.1200/jco.2010.28.15_suppl.1593
• Male breast cancer in veteran population: Retrospective analysis of VACCR database. Cite
  Subbiah S, Tashi T, Gonsalves W, Kalaiah M, Didwaniya N, Thota R, et al. Male breast cancer in veteran population: Retrospective analysis of VACCR database.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1031-1031 10.1200/jco.2010.28.15_suppl.1031
• Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer Cite
  Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 102:1391-1396 10.1038/sj.bjc.6605655
• Breast cancer in women under 40 years of age: A series of 57 cases from Northern Ireland Cite
  McAree B, O'Donnell M, Spence A, Lioe T, McManus D, Spence R. Breast cancer in women under 40 years of age: A series of 57 cases from Northern Ireland. The Breast. Elsevier BV; 2010; 19:97-104 10.1016/j.breast.2009.12.002
• Breast cancer incidence in Greek women in relation to ABO blood groups and Rh factor Cite
  Stamatakos M, Kontzoglou K, Safioleas P, Safioleas C, Manti C, Safioleas M. Breast cancer incidence in Greek women in relation to ABO blood groups and Rh factor. International Seminars in Surgical Oncology. Springer Science and Business Media LLC; 2009; 6 10.1186/1477-7800-6-14
• Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies Cite
  Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocrine-Related Cancer. Bioscientifica; 2009; 16:1197-1210 10.1677/erc-09-0043
• A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma Cite
  Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2007; 111:541-547 10.1007/s10549-007-9809-z
• The association of metabolic syndrome with triple-negative breast cancer Cite
  Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 121:479-483 10.1007/s10549-009-0591-y
• Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health–AARP Diet and Health Study Cite
  Park Y, Brinton LA, Subar AF, Hollenbeck A, Schatzkin A. Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health–AARP Diet and Health Study. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2009; 90:664-671 10.3945/ajcn.2009.27758
• Tea Consumption and Risk of Breast Cancer Cite
  Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea Consumption and Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:341-345 10.1158/1055-9965.epi-08-0819
• The Use of Herbal Preparations to Alleviate Climacteric Disorders and Risk of Postmenopausal Breast Cancer in a German Case-Control Study Cite
  Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M, et al. The Use of Herbal Preparations to Alleviate Climacteric Disorders and Risk of Postmenopausal Breast Cancer in a German Case-Control Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:2207-2213 10.1158/1055-9965.epi-09-0298
• Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women: The NIH-AARP Diet and Health Study Cite
  Lew JQ, Freedman ND, Leitzmann MF, Brinton LA, Hoover RN, Hollenbeck AR, et al. Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women: The NIH-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 170:308-317 10.1093/aje/kwp120
• Vitamin E Increases Biomarkers of Estrogen Stimulation When Taken With Tamoxifen Cite
  Peralta EA, Brewer AT, Louis S, Dunnington GL. Vitamin E Increases Biomarkers of Estrogen Stimulation When Taken With Tamoxifen. Journal of Surgical Research. Elsevier BV; 2009; 153:143-147 10.1016/j.jss.2008.03.030
• The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004 Cite
  Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:1763-1769 10.1158/1055-9965.epi-08-1082
• Progression from Normal Breast Pathology to Breast Cancer Is Associated with Increasing Prevalence of Mouse Mammary Tumor Virus-Like Sequences in Men and Women Cite
  Ford CE, Faedo M, Crouch R, Lawson JS, Rawlinson WD. Progression from Normal Breast Pathology to Breast Cancer Is Associated with Increasing Prevalence of Mouse Mammary Tumor Virus-Like Sequences in Men and Women. Cancer Research. American Association for Cancer Research (AACR); 2004; 64:4755-4759 10.1158/0008-5472.can-03-3804